Revelation Biosciences, Inc. — FY2022 Form 10-K
Business context and reporting period. This filing covers the fiscal year ended December 31, 2022; it does not provide separate fourth-quarter results. Revelation is a clinical-stage biotechnology company developing innate-immune therapeutics and diagnostics. It has no approved products and has generated no product revenue. The January 2022 business combination with Petra was accounted for as a reverse recapitalization, so the comparative financial statements principally reflect Revelation Sub’s operating history.
Financial results and liquidity
| Metric | FY2022 / December 31, 2022 | FY2021 / December 31, 2021 |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $5.38 million | $6.91 million |
| General and administrative expense | $5.49 million | $5.04 million |
| Total operating expenses / operating loss | $10.86 million | $11.95 million |
| Net loss | $10.83 million | $11.99 million |
| Net cash used in operating activities | $11.22 million | $11.09 million |
| Cash and cash equivalents at year-end | $5.25 million | $1.27 million |
| Total assets / total liabilities | $5.50 million / $4.45 million | $2.04 million / $2.14 million |
| Stockholders’ equity (deficit) | $1.05 million | $(0.10) million |
Gross margin and operating margin are not meaningful because the company reported no revenue. The filing reports no material investing cash outflow in 2022. Financing activities provided $15.20 million in 2022, including proceeds from the business combination, PIPE investment, and July offering, partly offset by the $7.65 million share repurchase and debt repayments. The filing does not present a clear standalone debt total at year-end; it reports that the promissory notes and convertible note were repaid during 2022. Current liabilities included $2.91 million of deferred underwriting commissions, $0.99 million of accrued expenses, and $0.55 million of accounts payable.
Material changes versus the prior comparable period
- Net loss narrowed by about $1.16 million, as operating expenses fell by about $1.09 million and other income improved by about $0.07 million.
- R&D expense declined $1.54 million, mainly because REVDx-501 development and personnel costs decreased; REVTx-99a clinical-study expense increased $0.32 million.
- G&A expense rose $0.45 million, primarily because of a $1.41 million increase in other expenses, which management attributed mainly to directors’ and officers’ insurance. Personnel and professional fees declined.
- Operating cash use was broadly similar year over year, while year-end cash increased by $3.98 million, principally reflecting financing inflows.
Outlook, risks, and unusual items
- Funding and going concern: Management and the auditor report substantial doubt about the company’s ability to continue as a going concern. Despite approximately $14.0 million of net proceeds from a February 2023 offering, management did not expect available cash to sustain operations for one year after the March 30, 2023 financial-statement issuance date. Additional financing is needed; the company warns that it may be unavailable on acceptable terms and could dilute shareholders or force program cuts.
- Development plans: Management planned Phase 1a studies of REVTx-300 and REVTx-100 in healthy volunteers in the second half of 2023, followed by Phase 1b patient studies in 2024. These are plans, not guaranteed milestones. REVTx-200 was in preclinical development; REVTx-99b was redirected to food allergies. The filing gives no clinical launch guidance for that food-allergy program.
- Program setbacks and prioritization: REVTx-99a’s Phase 2b primary endpoint in viral infection did not achieve statistical significance; further development was stopped. REVTx-99b’s allergic-rhinitis study met its safety/tolerability endpoint but exploratory efficacy endpoints were not met; development for that indication stopped. REVDx-501 diagnostic development was suspended to focus resources on therapeutics.
- Evidence and execution risk: Key candidates remain early-stage, and management notes that preclinical or earlier clinical results may not predict later outcomes. The company relies on CROs and contract manufacturers, and PHAD has one disclosed supplier without a long-term supply agreement. The company also has no internal sales organization.
- Litigation: LifeSci Capital seeks approximately $2.7 million in cash and $2.6 million in equity; the company disputes the claim, and the court denied the plaintiff’s summary-judgment motion in March 2023. A separate underwriter demand of $655,000 and $1.5 million of deferred underwriting fees were recorded as current liabilities. A-IR Clinical Research claims £1.6 million plus interest and costs, which the company disputes; a separate $150,000 Marwood claim was filed in January 2023. The filing says additional liabilities for the latter claims could not be determined and were not recorded.
- Post-year-end capital and share changes: The February 2023 offering generated approximately $14.0 million net proceeds, but also included substantial warrant issuance. A 1-for-35 reverse split took effect February 1, 2023, and authorized common shares increased from 100 million to 500 million. Nasdaq notified the company in February 2023 that it had regained applicable equity and bid-price compliance.
- Controls and audit: Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022. The auditor expressed an unmodified opinion on the financial statements but highlighted the going-concern uncertainty and did not audit internal-control effectiveness.
Important facts for investors to verify
- Cash runway and quarterly operating cash use after the February 2023 financing, including any further capital raises or spending reductions.
- Whether REVTx-300 and REVTx-100 studies began on schedule, and the resulting safety, biomarker, and proof-of-concept data.
- Current status and funding priorities for REVTx-200 and REVTx-99b, and whether suspended programs remain discontinued.
- Potential dilution and exercise terms from outstanding warrants, including warrants issued in the February 2023 offering, alongside the effects of the reverse split.
- Outcomes and any additional recorded liabilities in the LifeSci, underwriter, A-IR, and Marwood matters.
- Nasdaq listing compliance, including the company’s ability to maintain required equity and bid-price thresholds.